“Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors (Q3099129)
Jump to navigation
Jump to search
Project Q3099129 in Romania
Language | Label | Description | Also known as |
---|---|---|---|
English | “Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors |
Project Q3099129 in Romania |
Statements
7,171,850.97 Romanian Leu
0 references
1,434,370.1940000001 Euro
0.2 Euro
13 September 2021
0 references
8,493,897.32 Romanian Leu
0 references
1,698,779.4640000002 Euro
0.2 Euro
13 September 2021
0 references
84.44 percent
0 references
1 September 2016
0 references
30 November 2020
0 references
SPITALUL CLINIC JUDETEAN DE URGENTA " PIUS BRINZEU " TIMISOARA
0 references
Obiectivul principal al acestei propuneri de proiect este de a urma o abordare unica si de a dezvolta noi CARs care sunt potrivite în mod special pentru terapiile pe baza de celule NK, care reprezinta terapia personalizata anti-tumorala de ultimă ora. Ne asteptam ca acest proiect sa produca cereri de brevet internationale, care se vor traduce in cele din urma in comercializarea acestei tehnologii in Romania si in strainatate. Cunostintele obtinute in urma cercetarilor fundamentale in acest domeniu vor servi ulterior la stabilirea procedurile de lucru, reproductibile care vor ghida productia la nivel de GMP de celule pentru uz clinic pentru studii clinice suplimentare. In plus, ne propunem crearea primei banci de celule umane CAR-NKS, care poate fi dezvoltata si utilizata pentru studii clinice, in sprijinul medicinii personalizate in Romania. (Romanian)
0 references
The main objective of this project proposal is to follow a unique approach and develop new CARs that are especially suitable for NK cell therapies, which represent the latest personalised anti-tumor therapy. We expect this project to produce international patent applications, which will ultimately translate into the commercialisation of this technology in Romania and abroad. The knowledge obtained from fundamental researches in this field will then serve to establish reproducible working procedures that will guide the production of GMP cells for clinical use for further clinical trials. In addition, we aim to create the first CAR-NKS human cell bank, which can be developed and used for clinical trials, in support of personalised medicine in Romania. (English)
16 September 2021
0 references
L’objectif principal de cette proposition de projet est de suivre une approche unique et de développer de nouveaux CAR qui sont particulièrement adaptés aux thérapies cellulaires NK, qui représentent la dernière thérapie antitumorale personnalisée. Nous nous attendons à ce que ce projet produise des demandes de brevet internationales, ce qui se traduira en fin de compte par la commercialisation de cette technologie en Roumanie et à l’étranger. Les connaissances issues des recherches fondamentales dans ce domaine serviront ensuite à établir des procédures de travail reproductibles qui guideront la production de cellules BPF à des fins cliniques pour d’autres essais cliniques. En outre, nous visons à créer la première banque de cellules humaines CAR-NKS, qui peut être développée et utilisée pour des essais cliniques, en soutien à la médecine personnalisée en Roumanie. (French)
27 November 2021
0 references
Municipiul Timişoara, Romania
0 references
Identifiers
103662
0 references